NASDAQ: RNAAvidity Biosciences Inc Stock
$32.65+0.49 (+1.52%)
Updated Apr 30, 2025
RNA Price
$32.65
Fair Value Price
-$1.52
Market Cap
$3.92B
52 Week Low
$21.51
52 Week High
$56.00
P/E
-11.3x
P/B
2.75x
P/S
297.77x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.90M
Earnings
-$322.30M
Gross Margin
100%
Operating Margin
-2,957.71%
Profit Margin
-2,957.7%
Debt to Equity
0.1
Operating Cash Flow
-$301M
Beta
1.14
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
RNA Overview
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RNA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
RNA
Ranked#284 of 462
Ranked#284 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important RNA news, forecast changes, insider trades & much more!
RNA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RNA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RNA ($32.65) is overvalued by 2,242.21% relative to our estimate of its Fair Value price of -$1.52 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RNA ($32.65) is not significantly undervalued (2,242.21%) relative to our estimate of its Fair Value price of -$1.52 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RNA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RNA due diligence checks available for Premium users.
Valuation
RNA fair value
Fair Value of RNA stock based on Discounted Cash Flow (DCF)
Price
$32.65
Fair Value
-$1.52
Undervalued by
2,242.21%
RNA ($32.65) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RNA ($32.65) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RNA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RNA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-11.3x
Industry
-162.28x
Market
29.18x
RNA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.75x
Industry
4.45x
RNA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RNA's financial health
Profit margin
Revenue
$3.0M
Net Income
-$102.3M
Profit Margin
-3,439.5%
RNA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
RNA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.6B
Liabilities
$138.9M
Debt to equity
0.1
RNA's short-term assets ($1.54B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RNA's short-term assets ($1.54B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RNA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RNA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$99.9M
Investing
-$64.2M
Financing
$13.7M
RNA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RNA vs Biotech Stocks
Avidity Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.